
Version with Drug Affinity Complex — half-life of 7-10 days. A single dose maintains elevated GH levels for over a week.
Ranges cited in research literature. Not a usage recommendation. For research use only.
CJC-1295 with DAC is an analog of growth-hormone-releasing hormone (GHRH) developed by ConjuChem in the early 2000s. It starts from the active GHRH(1-29) fragment with four substitutions that protect it from enzymatic degradation, and adds at the C-terminus a lysine bearing a maleimidopropionic group: the “Drug Affinity Complex”, or DAC. That group reacts covalently with cysteine 34 of plasma albumin as soon as the peptide enters circulation.
The consequence is a half-life of 6 to 8 days, against the minutes of native GHRH or sermorelin. In the reference human pharmacokinetic study (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006), a single administration raised mean GH 2- to 10-fold for six days and IGF-1 1.5- to 3-fold for 9 to 11 days while preserving pulsatility. In other words, it does not replace the pulses; it makes all of them taller.
ConjuChem took the molecule to Phase 2 in GH deficiency and HIV-associated lipodystrophy, but development was halted in 2006 and it never reached approval. Because of its duration it is the GHRH analog under which GH and IGF-1 stay elevated the longest, which sharpens the usual considerations of this axis: fluid retention, effects on glucose and theoretical caution in tumor contexts. Renova distributes it for research only.
| Class | Long-acting GHRH(1-29) analog with Drug Affinity Complex |
| Structure | Mod GRF(1-29) [D-Ala2, Gln8, Ala15, Leu27] + Lys30-maleimidopropionic acid (DAC) |
| CAS | 863288-34-0 |
| Albumin binding | Covalent, to Cys34 of plasma albumin |
| Reported half-life | 6–8 days (versus ≈ 30 min without DAC) |
| Human data | Teichman et al., JCEM 2006: GH ×2–10 for 6 days; IGF-1 ×1.5–3 for 9–11 days |
| Clinical development | Phase 2 (ConjuChem) in GH deficiency and HIV lipodystrophy; halted in 2006 |
| Regulatory status | Not approved; GHRH and analogs on the WADA list (S2) |
DAC (Drug Affinity Complex) is a chemical group added to the end of the peptide that binds permanently to blood albumin. It turns a molecule lasting half an hour into one lasting almost a week. CJC-1295 without DAC (Mod GRF 1-29) is the same sequence without that group, with short, pulsatile action.
No, according to the Teichman study (2006): secretion remained pulsatile, but with every pulse taller and an elevated baseline GH for days. The difference from short analogs is the duration of the elevation, not loss of the pattern.
ConjuChem stopped the Phase 2 program in 2006 and the molecule never returned to pivotal trials. Since then it has existed only as a research compound, with well-described pharmacokinetics but no long-term human efficacy or safety data.
When the research line requires a sustained elevation of GH and IGF-1 with infrequent administration. If the aim is to reproduce physiological pulses with a short half-life, the option is Mod GRF 1-29, alone or with ipamorelin. Our CJC-1295 + Ipamorelin stack guide details the difference.
Related reading: CJC-1295 + Ipamorelin: The Most-Studied GH Stack · Peptide Stacking: Synergy, Sequencing, and Combinations
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty